Lipoatrophy is a thing of the past, or is it?

We describe the development of severe lipoatrophy in a patient treated with biphasic aspart. This complication of insulin therapy was common in the past with the use of animal insulins and became less common with the increasing purification of these and the introduction of recombinant human insulin. This patient developed severe lipoatrophy with the use of a premixed insulin containing the analogue insulin aspart. Lipoatrophy although rare can still occur even with the use of technologically advanced insulin preparations.